Results from a Phase 3 trial evaluating upadacitinib (Rinvoq) for giant-cell arteritis were published on 2025-01-01. The study, known as SELECT-GCA, assessed the safety and efficacy of the drug in participants with this condition, marking a significant step in the development of treatments for this inflammatory disease.
Background
The SELECT-GCA study investigated upadacitinib (Rinvoq) for the treatment of giant-cell arteritis.
What this means
The publication of these Phase 3 trial results for upadacitinib in giant-cell arteritis makes the detailed safety and efficacy data from the SELECT-GCA study available to clinicians, researchers, and patient advocates. This allows for a comprehensive review of the drug's performance in this specific patient population, informing future treatment decisions and research directions. The availability of these pivotal trial findings is crucial for understanding the potential role of upadacitinib in managing giant-cell arteritis.
Source
The information regarding the publication of these trial results was obtained from PubMed, a database of biomedical literature. The article, titled "A Phase 3 Trial of Upadacitinib for Giant-Cell Arteritis," was published on 2025-01-01 and is accessible via pubmed.ncbi.nlm.nih.gov.